|
C3ORF63 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 4.61319871192245E-11 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
5.84240000822689E-09 |
| Normal-vs-Stage2 |
1.73591000000028E-05 |
| Normal-vs-Stage3 |
2.68549960047437E-10 |
| Normal-vs-Stage4 |
2.08840000848198E-09 |
| Stage1-vs-Stage2 |
9.647600E-01 |
| Stage1-vs-Stage3 |
7.566300E-02 |
| Stage1-vs-Stage4 |
8.605500E-02 |
| Stage2-vs-Stage3 |
2.489800E-01 |
| Stage2-vs-Stage4 |
2.432600E-01 |
| Stage3-vs-Stage4 |
9.446600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
5.37130340205749E-11 |
| Normal-vs-AfricanAmerican |
1.243660E-03 |
| Normal-vs-Asian |
6.80299999999967E-07 |
| Caucasian-vs-AfricanAmerican |
4.232400E-01 |
| Caucasian-vs-Asian |
8.329000E-01 |
| AfricanAmerican-vs-Asian |
5.557000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.81830003778794E-10 |
| Normal-vs-Female |
5.8862004159721E-10 |
| Male-vs-Female |
5.862600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
7.12359999877066E-08 |
| Normal-vs-Age(41-60Yrs) |
8.11430034275418E-10 |
| Normal-vs-Age(61-80Yrs) |
1.10639997163986E-09 |
| Normal-vs-Age(81-100Yrs) |
2.481900E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.881450E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.760770E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.981000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.392200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.097200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.555200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.137760E-02 |
| Classical-VS-Follicular |
1.227840E-01 |
| Classical-VS-Other |
1.882040E-01 |
| Classical-VS-Normal |
1.12729999779404E-08 |
| Tall-VS-Follicular |
2.025200E-01 |
| Tall-VS-Other |
9.902000E-01 |
| Tall-VS-Normal |
3.86680000241668E-08 |
| Follicular-VS-Other |
5.467200E-01 |
| Follicular-VS-Normal |
1.31109999967904E-07 |
| Other-VS-Normal |
1.636950E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
4.64460025995095E-10 |
| Normal-vs-N1 |
5.56629997650049E-09 |
| N0-vs-N1 |
5.133400E-01 |
|
|
